ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

This study has been completed.

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00168168

Purpose

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Condition	Intervention
Peripheral Stem Cell/Marrow Transplant	Drug: G-CSF/Filgrastim

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title:	ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Further study details as provided by Alberta Cancer Board:

Eligibility

Criteria

Inclusion Criteria:

over age 18
autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168168

Locations

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Meluka Game, MD

Alberta Cancer Board

More Information

Study ID Numbers:	HE-10-0053
Study First Received:	September 14, 2005
Last Updated:	September 22, 2008
ClinicalTrials.gov Identifier:	NCT00168168
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

G-CSF
Filgrastim
Engraftment time
Autologus transplant

ClinicalTrials.gov processed this record on January 13, 2009